Systemic risk profiles of topical ruxolitinib and oral Janus kinase inhibitors in patients with atopic dermatitis: A retrospective cohort study from the TriNetX network
{{output}}
Background: Topical ruxolitinib is a Janus-activated kinase (JAK) inhibitor used to treat atopic dermatitis. The U.S. Food and Drug Administration issued a boxed warning for topical ruxolitinib, assuming it carries similar risks ... ...
